These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7911048)

  • 1. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation.
    Neubauer MA; Benyunes MC; Thompson JA; Bensinger WI; Lindgren CG; Buckner CD; Fefer A
    Bone Marrow Transplant; 1994 Mar; 13(3):311-6. PubMed ID: 7911048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A
    Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
    Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of circulating hematopoietic progenitor cells after peripheral blood stem cell transplantation.
    Mahmut N; Katayama Y; Takenaka K; Teshima T; Ohno Y; Imajyo K; Hara M; Shinagawa K; Ishimaru F; Ikeda K; Niiya K; Harada M
    Int J Hematol; 1999 Jan; 69(1):36-42. PubMed ID: 10641441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR; Parreira A; Ascensão JL
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
    Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
    Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantation.
    Fegan C; Thomas H; Bailey-Wood R; Coleman S; Phillips S; Hoy T; Whittaker JA
    Bone Marrow Transplant; 1995 Aug; 16(2):277-81. PubMed ID: 7581148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of interleukin-12 with lung cancer and malignant lymphoma undergoing autologous peripheral blood stem cell transplantation.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Jan; 128(1):29-36. PubMed ID: 11862469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome.
    Martín C; Torres A; León A; Rubio V; Alvarez MA; Herrera C; Jean-Paul E; Correa MA; Rojas R; Campos R; Serrano J; Romero R; Román J; Guzmán JL; Flores R; Falcón M; Martínez F; Gómez P
    Bone Marrow Transplant; 1998 Feb; 21(4):375-82. PubMed ID: 9509972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limiting dilution analysis of lymphokine-activated killer cell precursor frequencies in peripheral blood lymphocytes of cancer patients receiving interleukin-2 therapy.
    Albertini MR; Oettel KR; Weil-Hillman G; Lindstrom MJ; Schell K; Hank JA; Sondel PM
    J Biol Response Mod; 1990 Oct; 9(5):456-62. PubMed ID: 2254758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J; Gulati SC
    Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro generation of cytotoxic effectors activated by interleukin 2 (IL-2): comparison of autologous peripheral blood stem cells (PBSC) from adults and children.
    Valteau-Couanet D; Angevin E; Leboulaire C; Beaussier PS; Bayle C; Hartmann O; Beaujean F
    Bone Marrow Transplant; 2001 Apr; 27(8):869-75. PubMed ID: 11477446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new strategy using autologous dendritic cells and lymphokine-activated killer cells for cancer immunotherapy: efficient maturation of DCs by co-culture with LAK cells in vitro.
    Yano Y; Ueda Y; Itoh T; Fuji N; Okugawa K; Naito K; Imura K; Kohara J; Hayashi T; Nakane K; Matsuura Y; Kawai K; Yamagishi H
    Oncol Rep; 2006 Jul; 16(1):147-52. PubMed ID: 16786138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
    Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the T-helper cell 1/T-helper cell 2 balance of peripheral T-helper cells after autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma.
    Mukai M; Bohgaki T; Kondo M; Notoya A; Kohno M
    Ann Hematol; 2001 Dec; 80(12):715-21. PubMed ID: 11797111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
    Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Triozzi PL; Tucker F; Benzies T; Balcerzak SP
    Bone Marrow Transplant; 1996 Jul; 18(1):47-52. PubMed ID: 8831995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-12 induced cytolytic activity in lymphocytes from recipients of autologous and allogeneic stem cell transplants.
    Lindgren CG; Thompson JA; Robinson N; Keeler T; Gold PJ; Fefer A
    Bone Marrow Transplant; 1997 May; 19(9):867-73. PubMed ID: 9156259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.